SCHEMBL419463

SCHEMBL419463

O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.37
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624112 1.00 MPI (0.37) MPIALDH1A1
Bicarbonate SCHEMBL8384988 0.98 MPI (0.36) MPIALDH1A1
Bicarbonate SCHEMBL8384375 0.98 MPI (0.36) MPIALDH1A1
SCHEMBL1607595 0.94 MPI (0.38) MPIALDH1A1
SCHEMBL1032576 0.85 ALDH1A1 (0.40) ALDH1A1
SCHEMBL789905 0.82 MPI (0.36) MPI
SCHEMBL426315 0.82 MPI (0.36) MPIALDH1A1
SCHEMBL2884877 0.82 MPI (0.36) MPIALDH1A1
SCHEMBL2354360 0.82 MPI (0.36) MPI
SCHEMBL215097 0.82 MPI (0.36) MPIALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11931497-B2 System and method for preparing peritoneal dialysis fluid at the time of use BAXTER INTERNATIONAL INC. (US) 2024-03-19 US disclosed
US-20230202973-A1 BARNESIN A, DERIVATIVES AND USES THEREOF LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. (HKI) (DE) 2023-06-29 US disclosed
US-20220211926-A1 SYSTEM AND METHOD FOR PREPARING PERITONEAL DIALYSIS FLUID AT THE TIME OF USE VANTIVE US HEALTHCARE LLC 2022-07-07 US disclosed
US-11311657-B2 Dialysis system for mixing treatment fluid at time of use BAXTER INTERNATIONAL INC. (US) 2022-04-26 US disclosed
EP-3762360-A1 BARNESIN A, DERIVATIVES AND USES THEREOF Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (DE) 2021-01-13 EP disclosed
US-20200231562-A1 NOVEL MACROLIDE ANTIBIOTICS LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. (HKI) (DE) 2020-07-23 US disclosed
US-10472326-B2 PQSR modulators Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2019-11-12 US disclosed
US-20190298906-A1 DIALYSIS SYSTEM FOR MIXING TREATMENT FLUID AT TIME OF USE VANTIVE US HEALTHCARE LLC 2019-10-03 US disclosed
WO-2019170705-A1 BARNESIN A, DERIVATIVES AND USES THEREOF LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. - HANS-KNÖLL-INSTITUT - (DE) 2019-09-12 WO disclosed
EP-3536684-A1 BARNESIN A, DERIVATIVES AND USES THEREOF Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (DE) 2019-09-11 EP disclosed
EP-0619704-A4 METHOD AND COMPOSITION FOR TREATING TUMORS HAVING HIGH TYROSINASE ACTIVITY. RUBIN DAVID (US) 1997-03-26 EP disclosed
US-5420107-A Fluids, inorganic lactic acid salts and administering BROOKS, GEORGE A. 1995-05-30 US disclosed
EP-0619704-A1 METHOD AND COMPOSITION FOR TREATING TUMORS HAVING HIGH TYROSINASE ACTIVITY Rubin, David (US) 1994-10-19 EP disclosed
US-5340803-A Method and compositions for treating tumors having high tyrosinase activity CO ENZYME TECHNOLOGY LTD. (US) 1994-08-23 US disclosed
US-5240914-A Method and compositions for inhibiting tumor cell metabolism Schwimmer, Adolph (US) 1993-08-31 US disclosed
WO-1993008688-A1 METHOD AND COMPOSITION FOR TREATING TUMORS HAVING HIGH TYROSINASE ACTIVITY SCHWIMMER, ADOLPH (US) 1993-05-13 WO disclosed
US-4584368-A β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production Schwimmer, Adolf W. (IL) 1986-04-22 US disclosed
US-4337760-A Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals Schwimmer, Adolf (IL) 1982-07-06 US disclosed
US-4327074-A Method for diagnosis and selective treatment of infections of bacteria having β-glucuronidase activity Schwimmer, Adolf W. 1982-04-27 US disclosed
WO-1980000791-A1 B-GLUCURONIDASE ACTIVITY AND/OR PH-DEPENDENT PHARMACEUTICALS AND THEIR METHODS OF PRODUCTION AND USE FOR SELECTIVE TREATMENT OF DISEASES SCHWIMMER A (US) 1980-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231562-A1 NOVEL MACROLIDE ANTIBIOTICS MRPL21, MRPS18A, LSS MPI 1066/4885ALDH1A1 4483/4885
US-20230202973-A1 BARNESIN A, DERIVATIVES AND USES THEREOF SERPINB1, SERPINA3, CMA1 MPI 1788/4885ALDH1A1 960/4885
US-10472326-B2 PQSR modulators QARS1, SRPRA, MRPS35 MPI 1289/4885ALDH1A1 4707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.